The underestimated role of somatostatin analogs in the NETTER-1 trial

Sara Pusceddu¹, Roberto Buzzoni¹, Filippo de Braud^{2

1}

Affiliations

¹ University of Milan, Fondazione IRCCS "Istituto Nazionale dei Tumori", Via G. Venezian 1, 20133 Milan, Italy.
² Department of Medical Oncology Unit 1, GEP-ENETS Center of Excellence, "Istituto Nazionale Tumori", Milan, Italy.

Editorial

Sara Pusceddu et al. Future Oncol. 2017 Jun.

. 2017 Jun;13(15):1287-1289.

doi: 10.2217/fon-2017-0130. Epub 2017 May 11.

Sara Pusceddu¹, Roberto Buzzoni¹, Filippo de Braud^{2

1}

¹ University of Milan, Fondazione IRCCS "Istituto Nazionale dei Tumori", Via G. Venezian 1, 20133 Milan, Italy.
² Department of Medical Oncology Unit 1, GEP-ENETS Center of Excellence, "Istituto Nazionale Tumori", Milan, Italy.

No abstract available

Keywords: NETTER-1; PRRT; clinical trials; lanreotide; neuroendocrine tumors; octreotide; somatostatin analogs.

Comment on

Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Strosberg J, et al. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. N Engl J Med. 2017. PMID: 28076709 Free PMC article. Clinical Trial.